Immunologic Resolution of Human Chronic Graft-versus-Host Disease

Slides:

Advertisements

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Advertisements

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome Joseph Delano F. Robles, Daniel.

Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients Takahiro.

How to Treat MDS without Stem Cell Transplantation

Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.

Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation Imran Ahmad,

Vaccination of Children following Allogeneic Stem Cell Transplantation

Altered Homeostasis of CD4+ Memory T Cells in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Chronic Graft-versus-Host Disease Enhances T Cell.

Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells.

Elevated Numbers of Immature/Transitional CD21− B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,

Long-Term Immune Reconstitution of Naive and Memory T Cell Pools after Haploidentical Hematopoietic Stem Cell Transplantation Rita I. Azevedo, Maria.

B Cells in Chronic Graft-versus-Host Disease

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Sabina Kersting, Leo F. Verdonck

Genital Chronic Graft-versus-Host Disease in Females: A Cross-Sectional Study Eva Smith Knutsson, Yvonne Björk, Anna-Karin Broman, Lotti Helström, Anne-Marie.

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease Sean Robinson.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation Joseph Pidala, Marcie Tomblyn, Taiga.

LONG TERM Outcomes of Pediatric Patients with Malignant and NON-Malignant Disorders Receiving Α/Β T-CELL Depleted HLA-Haploidentical Hematopoietic STEM.

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Effect of Ex Vivo Culture of CD34+ Bone Marrow Cells on Immune Reconstitution of XSCID Dogs Following Allogeneic Bone Marrow Transplantation Douglas.

Late-Onset Colitis after Cord Blood Transplantation Is Consistent with Graft-Versus-Host Disease: Results of a Blinded Histopathological Review Filippo.

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

Biology of Blood and Marrow Transplantation

The Expression of Th17-Associated Cytokines in Human Acute Graft-versus-Host Disease Yuejun Liu, Yifeng Cai, Lan Dai, Guanghua Chen, Xiao Ma, Ying Wang,

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

B Cells and Transplantation: An Educational Resource

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Rammurti.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Persistence of host dendritic cells after transplantation is associated with graft-versus- host disease Geoffrey W. Chan, Gullu Gorgun, Kenneth B. Miller,

A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus- Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients.

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

CD3+/Tregs Ratio in Donor Grafts Is Linked to Acute Graft-versus-Host Disease and Immunologic Recovery after Allogeneic Peripheral Blood Stem Cell Transplantation

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease

What is quality in a transplant program?

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Blood and Marrow Transplant Handbook

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Alveolar Hemorrhage and Acute Graft-versus-Host Disease

Mammen Chandy Biology of Blood and Marrow Transplantation

Successful Immune Reconstitution Decreases Leukemic Relapse and Improves Survival in Recipients of Unrelated Cord Blood Transplantation Robertson Parkman,

Early and Late Extensive Chronic Graft-versus-Host Disease in Children Is Characterized by Different Th1/Th2 Cytokine Profiles: Findings of the Children's.

Immunologic Recovery in Children after Alternative Donor Allogeneic Transplantation for Hematologic Malignancies: Comparison of Recipients of Partially.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

Sarah Nikiforow, Haesook T

Mary Eapen Biology of Blood and Marrow Transplantation

In Memoriam: E. Donnall Thomas

Daniel Couriel, Chitra Hosing, Rima Saliba, Elizabeth J

Presentation transcript:

Immunologic Resolution of Human Chronic Graft-versus-Host Disease Kris M. Mahadeo, Bernadette Masinsin, Neena Kapoor, Ami J. Shah, Hisham Abdel-Azim, Robertson Parkman Biology of Blood and Marrow Transplantation Volume 20, Issue 10, Pages 1508-1515 (October 2014) DOI: 10.1016/j.bbmt.2014.06.030 Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (A) Schema for immunophenotypic analyses of CD4 T lymphocytes, Tcons (CD4+, CD127+, CD25−), and Tregs (CD4+, CD127−, CD25+) from an HSCT recipient with active cGVHD. (I) FoxP3 staining of Tcons. (II) control IgG staining of Tregs. (III) Fox P3 staining of Tregs with identification of rTregs (CD4+, CD127−, CD25+, CD45RA+, FoxP3+; P12), aTregs (CD4+, CD127−, CD25+, CD45RA−, FoxP3+++; P9), and subpopulation A (A: CD4+, CD127−, CD25+, CD45RA+, FoxP3−; Q1-1). (B) Immunophenotypic detection of RTEs (CD4+, CD45RA+, CD31+) in the rTregs (P12). Biology of Blood and Marrow Transplantation 2014 20, 1508-1515DOI: (10.1016/j.bbmt.2014.06.030) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 (A) Determination of the frequency of CD4 T lymphocytes, Tcons, and Tregs in group 1, 2, 3, and 4 recipients and normal pediatric donors (D). Results are presented as percentage of total lymphocytes (CD4) or of CD4 T lymphocytes (Tcons and Tregs). (B) Determination of the absolute number of CD4 T lymphocytes (cells/μL) in group 1, 2, 3, and 4 recipients and normal pediatric donors (D). Biology of Blood and Marrow Transplantation 2014 20, 1508-1515DOI: (10.1016/j.bbmt.2014.06.030) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 (A) Determination of the frequency of rTregs in group 1, 2, 3, and 4 recipients and normal donors (D), presented as percentages of CD4 T lymphocytes and Tregs, and determination of the absolute number of rTregs in group 1, 2, 3, and 4 recipients and normal donors (D), presented as rTregs/μL. (B) Determination of the frequency of aTregs in group 1, 2, 3, and 4 recipients and normal donors (D), presented as percentages of CD4 T lymphocytes and Tregs. Biology of Blood and Marrow Transplantation 2014 20, 1508-1515DOI: (10.1016/j.bbmt.2014.06.030) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 (A) Determination of the frequency of RTEs (CD4+, CD45RA+, CD31+) in CD4 T lymphocytes, Tcons, and Tregs in group 1, 2, 3, and 4 recipients and normal donors (D). Results are presented as percentage of RTEs in the total population. (B) RTE frequency, absolute number, and percentage of rTregs in group 1, 2, 3, and 4 recipients and normal donors (D). Results are presented as percentage of CD4 T lymphocytes, RTEs/μL, and percentage of rTregs. (C) Frequency and absolute numbers of RTEs in the subpopulation A T lymphocytes of group 1, 2, 3, and 4 recipients and normal donors (D). Results are presented as percentage of CD4 T lymphocytes and RTEs/μL. Biology of Blood and Marrow Transplantation 2014 20, 1508-1515DOI: (10.1016/j.bbmt.2014.06.030) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 (A) Linear regression analysis of the frequency of rTregs versus time (in months) from HSCT in group 1, 3, and 4 recipients. (B) Linear regression analysis of the frequency of RTEs in rTregs versus time (in months) from HSCT in group 1, 3, and 4 recipients. Biology of Blood and Marrow Transplantation 2014 20, 1508-1515DOI: (10.1016/j.bbmt.2014.06.030) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions